The talk on the town.

Mental health vocal biomarker startup has raised $20 million in a Series A funding round led by Insight Partners. The new investment will go toward scaling Kintsugi and improving its voice test for detecting subtle signs of anxiety, depression, and other potential mental health issues.

Kintsugi, a startup that aims to identify signs of depression and anxiety using vocal biomarkers, scored $20 million in Series A funding. The latest round comes about six months after the company announced it had raised $8 million in seed funding.

Kintsugi Founder & CEO, Grace Chang, talks about listening to people's needs and bridging the critical gap in mental healthcare in Crunchbase's Female Founders Series.

Kintsugi’s Founder & Chief Scientist Rima Seiilova-Olson was invited by The National AI Research Resource (NAIRR) and the White House Office of Science and Technology Policy to take part in a panel discussion on the democratization of AI research, education, and innovation for communities that have been traditionally underserved or underrepresented.

Kintsugi’s Founder & Chief Scientist Rima Seiilova-Olson was invited by Techstars for an open conversation on building companies at the cutting edge of science and tech in the mental health space.